摘要
目的观察大剂量坦索罗辛治疗BPH引起LUTS的临床效果。方法采用前瞻性、随机对照研究，观察期为4周。261例经诊断为BPH引起LUTS的患者简单随机分为两组，分别采用口服坦索罗辛0．2mg每晚1次（126例）或0．4mg每晚1次（135例），比较治疗前后的IPSS评分和Qmax。结果0．2mg组IPSS由治疗前的17．72±2．50降至10．21±1．95，平均下降7．59±2．74；Qmax由（8．78±3．70）ml／s升至（12．74±2．99）ml／s，平均上升（4．31±3．01）ml／s；治疗前后比较差异均有统计学意义（P〈0．05）。0．4mg组IPSS由治疗前的19．24±3．22降至11．21±3．02，平均下降8．49±3．73；Qmax由（7．74±1．97）ml／s升至（12．04±2．46）ml／s，平均上升（4．73±2．97）ml／s；治疗前后比较差异均有统计学意义（P〈0．05）。两组IPSS评分变化差异无统计学意义（P〉0．05），Qmax变化差异有统计学意义（P〈0．05）。将两组患者按体质量≤55．0、55．1～65．0、65．1—75．0、〉75．0kg进一步分组，发现体质量65．1～75．0、〉75．0kg两组间IPSS和Qmax变化情况比较差异均有统计学意义（P〈0．05）。两组间的不良反应发生率差异无统计学意义（P〉0．05）。结论对于体质量≤65．0kg的患者而言，使用大剂量坦索罗辛对于改善BPH引起的LUTS并不能带来显著益处，但对于体质量≥65．1kg患者可建议增加坦索罗辛的剂量。
Objective To evaluate the effect of increasing doses of tamsulosin in lower urinary tract symptom （LUTS） of benign prostatic hyperplasia （BPH）. Methods A prospective self-controlled clinical trail was performed. Two hundred and sixty-one patients who had LUTS of BPH were enrolled in this prospective 4 weeks study of tamsulosin. The patients were randomly divided into 2 groups ： took tamsulosin 0.2 mg QN （n = 126, group A） and 0.4 mg QN （n = 135, group B） respectively. The IPSS score and maximum flow rate before and after treatment were compared between the 2 groups. Results The IPSS score of group A decreased from 17.72 ± 2.50 to 10.21 ± 1.95, average decreased 7.59 ± 2.74 ; maximum flow rate was elevated from （8.78 ± 3.70） ml/s to （ 12.74 ± 2.99） ml/s, average increased （4.31 ± 3.01 ） ml/s. The IPSS score of group B decreased from 19.24 ± 3.22 to 11.21 ± 3.02, average decreased 8.49 ± 3.73; maximum flow rate was elevated from （7.74 ± 1.97） ml/s to （12.04 ± 2.46） ml/s, average increased （4.73 ± 2.97） ml/s. There was no significant difference of the changes of IPSS score between the 2 groups （P 〉 0.05） , but there was a significant difference of the changes of maximum flow rate between the 2 groups （ P 〈 0.05 ）. The results was further analyzed by sub grouped （ by patient body weight, divided into ±〈55.0 kg, 55.1 -65.0 kg, 65.1 -75.0 kg, 〉 75.0 kg group）. There were significant differences of the changes of IPSS score and maximum flow rate between the 2 groups in 65.1 - 75.0 kg and 〉 75.0 kg subgroups （P 〈0.05 ）. The incidence of side effects between the 2 groups was not significantly different （P 〉 0.05 ）. Conclusions For most patients, the use of high-dose tamsulosin in improving LUTS caused by BPH can not bring significant benefits. But if the patient＇s weight is more than 65.0 kg, increasing the dose of tamsulosin is suggested for consideration.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2012年第2期117-119,共3页
Chinese Journal of Urology
关键词
前列腺增生
下尿路症状
坦索罗辛
治疗剂量
Prostatic hyperplasia
Lower urinary tract symptoms
Tamsulosin
Therapeutic dose
